Why the study?
Patients with STEMI presenting with cardiogenic shock have high mortality, but relevant early prognostic factors despite revascularization are poorly investigated.
Cohort (n=1,222)
No
Absolute Event Rate: 33% vs 3%
p-value: p=< 0.01
In STEMI patients with cardiogenic shock, older age, longer ischemia time, and lack of final TIMI 2-3 flow are independent predictors of 30-day mortality despite primary PCI.
BACKGROUND: Despite prognostic improvements in ST-elevation myocardial infarction (STEMI), patients presenting with cardiogenic shock (CS) have still high mortality. Which are the relevant early prognostic factors despite revascularization in this high-risk population is poorly investigated. METHODS: We analyzed STEMI patients treated with primary percutaneous coronary intervention (PCI) and enrolled at the University Hospital of Trieste between 2012 and 2018. A decision tree based on data available at first medical contact (FMC) was built to stratify patients for 30-day mortality. Multivariate analysis was used to explore independent factors associated with 30-day mortality. RESULTS: Among 1222 STEMI patients consecutively enrolled, 7.5% presented with CS. CS compared with no-CS patients had worse 30-day mortality (33% vs 3%, P < 0.01). Considering data available at FMC, CS patients with a combination of age ≥76 years, anterior STEMI and an expected ischemia time > 3 h and 21 min were at the highest mortality risk, with a 30-day mortality of 85.7%. In CS, age (OR 1.246; 95% CI 1.045-1,141; P = 0.003), final TIMI flow 2-3 (OR 0.058; 95% CI 0.004-0.785; P = 0.032) and Ischemia Time (OR = 1.269; 95% CI 1.001-1.609; P = 0.049) were independently associated with 30-day mortality. CONCLUSIONS: In a contemporary real-world population presenting with CS due to STEMI, age is a relevant negative factor whereas an early and successful PCI is positively correlated with survival. However, a subgroup of elderly patients had severe prognosis despite revascularization. Whether pPCI may have an impact on survival in a very limited number of irreversibly critically ill patients remains uncertain and the identification of irreversibly shocked patients remains nowadays challenging.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=1,222). Cardiogenic shock vs. No cardiogenic shock was evaluated on 30-day mortality (p=< 0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: